Infinity Pharmaceuticals, Inc. provided unaudited earnings guidance for the full-year 2016. The company expects revenue for 2016 to range from $225 million to $245 million, assuming the achievement of $200 million in anticipated regulatory milestones under the company's collaboration with AbbVie: $125 million associated with the acceptance of the first NDA submission and $75 million associated with the acceptance of the first MAA submission, both expected in the fourth quarter of 2016. It expects net income for 2016 to range from $15 million to $35 million.